David Haselwood Focused on developing disruptive technologies that have the opportunity to revolutionize major segments of healthcare. Currently this includes developing breakthrough personalized cancer therapeutics (Gradalis, Inc.), changing the way advanced biotherapeutic manufacturing facilities